DEV-19. THE ROLE OF COMBAT (COMBINED ORAL METRONOMIC BIODIFFERENTIATING ANTIANGIOGENIC TREATMENT) IN HIGH-RISK AND RELAPSED MEDULLOBLASTOMA: A SINGLE INSTITUTION EXPERIENCE